Cytek Biosciences (CTKB) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Business overview and financial performance

• Operates in the life science tools sector with Full Spectral Profiling (FSP) technology as its core innovation, supporting four business pillars: instruments, applications, bioinformatics, and clinical solutions.

• Over 2,800 instruments deployed globally in more than 70 countries, with a customer base exceeding 1,500 and over 2,100 publications utilizing its technology.

• Achieved trailing 12-month revenue above $200 million, with adjusted EBITDA profitability of $21 million and positive cash flow; maintains $278 million in cash after $15 million in share buybacks.

• 2023 revenue guidance is $203–$210 million, with 60% of revenue from pharma, biotech, CROs, and hospitals, and 40% from academia.

• Geographic revenue split: 47% North America, 33% Europe, and 20% APAC (including China and India).

Product portfolio and technology differentiation

• Instrument sales account for 70% of revenue, led by Aurora (high-end) and Northern Lights (entry/mid-level, clinical), with clinical approvals in China and Europe.

• Remaining 30% of revenue comes from reagents, software, and services, with services representing 25% and recurring revenue driven by reagent applications.

• FSP technology enables high-dimensional cell analysis, reducing sample and reagent needs, and supports standardization across global labs.

• Tools are widely used in oncology, vaccine development, immunology, and environmental sciences, with applications extending to marine biology and pollution studies.

• Bioinformatics platform launched two years ago has over 12,000 users, enhancing panel design and data management.

Operational strategy and growth drivers

• Maintains gross margin target of 60% despite high capital instrument mix, focusing on operational excellence and free cash flow maximization.

• Invests 20% of revenue in R&D to sustain technology leadership and drive new product launches.

• Pursues acquisitions to expand capabilities, including reagent and imaging technology companies, and recently a UK-based service business.

• FSP technology is recognized as disruptive, creating a new high-dimensional cell analysis market segment and shifting the industry toward full spectral solutions.

• User group meeting scheduled for December 5th in Boston to engage with customers and showcase technology.